These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 39508845)

  • 1. HLA class II neoantigen presentation for CD4
    Matsumoto S; Tsujikawa T; Tokita S; Mohamed Bedeir M; Matsuo K; Hata F; Hirohashi Y; Kanaseki T; Torigoe T
    Oncoimmunology; 2024 Dec; 13(1):2404665. PubMed ID: 39508845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteogenomic identification of an immunogenic HLA class I neoantigen in mismatch repair-deficient colorectal cancer tissue.
    Hirama T; Tokita S; Nakatsugawa M; Murata K; Nannya Y; Matsuo K; Inoko H; Hirohashi Y; Hashimoto S; Ogawa S; Takemasa I; Sato N; Hata F; Kanaseki T; Torigoe T
    JCI Insight; 2021 Jul; 6(14):. PubMed ID: 34185709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IL-6 down-regulates HLA class II expression and IL-12 production of human dendritic cells to impair activation of antigen-specific CD4(+) T cells.
    Ohno Y; Kitamura H; Takahashi N; Ohtake J; Kaneumi S; Sumida K; Homma S; Kawamura H; Minagawa N; Shibasaki S; Taketomi A
    Cancer Immunol Immunother; 2016 Feb; 65(2):193-204. PubMed ID: 26759006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of high CD4-positive T cell infiltration with mutations in HLA class II-regulatory genes in microsatellite-unstable colorectal cancer.
    Surmann EM; Voigt AY; Michel S; Bauer K; Reuschenbach M; Ferrone S; von Knebel Doeberitz M; Kloor M
    Cancer Immunol Immunother; 2015 Mar; 64(3):357-66. PubMed ID: 25445815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficient presentation of known HLA class II-restricted MAGE-A3 epitopes by dendritic cells electroporated with messenger RNA encoding an invariant chain with genetic exchange of class II-associated invariant chain peptide.
    Bonehill A; Heirman C; Tuyaerts S; Michiels A; Zhang Y; van der Bruggen P; Thielemans K
    Cancer Res; 2003 Sep; 63(17):5587-94. PubMed ID: 14500399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of immunogenic HLA class I and II neoantigens using surrogate immunopeptidomes.
    Tokita S; Fusagawa M; Matsumoto S; Mariya T; Umemoto M; Hirohashi Y; Hata F; Saito T; Kanaseki T; Torigoe T
    Sci Adv; 2024 Sep; 10(38):eado6491. PubMed ID: 39292790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment.
    Newey A; Griffiths B; Michaux J; Pak HS; Stevenson BJ; Woolston A; Semiannikova M; Spain G; Barber LJ; Matthews N; Rao S; Watkins D; Chau I; Coukos G; Racle J; Gfeller D; Starling N; Cunningham D; Bassani-Sternberg M; Gerlinger M
    J Immunother Cancer; 2019 Nov; 7(1):309. PubMed ID: 31735170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endogenous HLA class II epitopes that are immunogenic in vivo show distinct behavior toward HLA-DM and its natural inhibitor HLA-DO.
    Kremer AN; van der Meijden ED; Honders MW; Goeman JJ; Wiertz EJ; Falkenburg JH; Griffioen M
    Blood; 2012 Oct; 120(16):3246-55. PubMed ID: 22889757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dendritic cells in colorectal cancer correlate with other tumor-infiltrating immune cells.
    Dadabayev AR; Sandel MH; Menon AG; Morreau H; Melief CJ; Offringa R; van der Burg SH; Janssen-van Rhijn C; Ensink NG; Tollenaar RA; van de Velde CJ; Kuppen PJ
    Cancer Immunol Immunother; 2004 Nov; 53(11):978-86. PubMed ID: 15197496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoantigen-reactive T cells exhibit effective anti-tumor activity against colorectal cancer.
    Yu Y; Zhang J; Ni L; Zhu Y; Yu H; Teng Y; Lin L; Xue Z; Xue X; Shen X; Song H; Su X; Sun W; Cai Z
    Hum Vaccin Immunother; 2022 Dec; 18(1):1-11. PubMed ID: 33689574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SV-BR-1-GM, a Clinically Effective GM-CSF-Secreting Breast Cancer Cell Line, Expresses an Immune Signature and Directly Activates CD4
    Lacher MD; Bauer G; Fury B; Graeve S; Fledderman EL; Petrie TD; Coleal-Bergum DP; Hackett T; Perotti NH; Kong YY; Kwok WW; Wagner JP; Wiseman CL; Williams WV
    Front Immunol; 2018; 9():776. PubMed ID: 29867922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Landscape of helper and regulatory antitumour CD4
    Oliveira G; Stromhaug K; Cieri N; Iorgulescu JB; Klaeger S; Wolff JO; Rachimi S; Chea V; Krause K; Freeman SS; Zhang W; Li S; Braun DA; Neuberg D; Carr SA; Livak KJ; Frederick DT; Fritsch EF; Wind-Rotolo M; Hacohen N; Sade-Feldman M; Yoon CH; Keskin DB; Ott PA; Rodig SJ; Boland GM; Wu CJ
    Nature; 2022 May; 605(7910):532-538. PubMed ID: 35508657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of acid ceramidase regulates MHC class II antigen presentation and suppression of autoimmune arthritis.
    Zhao D; Hajiaghamohseni LM; Liu X; Szulc ZM; Bai A; Bielawska A; Norris JS; Reddy SV; Hannun YA; Haque A
    Cytokine; 2020 Nov; 135():155219. PubMed ID: 32738771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Defining HLA-II Ligand Processing and Binding Rules with Mass Spectrometry Enhances Cancer Epitope Prediction.
    Abelin JG; Harjanto D; Malloy M; Suri P; Colson T; Goulding SP; Creech AL; Serrano LR; Nasir G; Nasrullah Y; McGann CD; Velez D; Ting YS; Poran A; Rothenberg DA; Chhangawala S; Rubinsteyn A; Hammerbacher J; Gaynor RB; Fritsch EF; Greshock J; Oslund RC; Barthelme D; Addona TA; Arieta CM; Rooney MS
    Immunity; 2019 Oct; 51(4):766-779.e17. PubMed ID: 31495665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Melanoma-specific CD4+ T lymphocytes recognize human melanoma antigens processed and presented by Epstein-Barr virus-transformed B cells.
    Topalian SL; Rivoltini L; Mancini M; Ng J; Hartzman RJ; Rosenberg SA
    Int J Cancer; 1994 Jul; 58(1):69-79. PubMed ID: 7516926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Malignant glioma cells use MHC class II transactivator (CIITA) promoters III and IV to direct IFN-gamma-inducible CIITA expression and can function as nonprofessional antigen presenting cells in endocytic processing and CD4(+) T-cell activation.
    Soos JM; Krieger JI; Stüve O; King CL; Patarroyo JC; Aldape K; Wosik K; Slavin AJ; Nelson PA; Antel JP; Zamvil SS
    Glia; 2001 Dec; 36(3):391-405. PubMed ID: 11746775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation of mammaglobin-A-specific CD4 T cells and identification of candidate CD4 epitopes for breast cancer vaccine strategies.
    Viehl CT; Frey DM; Phommaly C; Chen T; Fleming TP; Gillanders WE; Eberlein TJ; Goedegebuure PS
    Breast Cancer Res Treat; 2008 May; 109(2):305-14. PubMed ID: 17653857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inflammatory cells infiltrating human colorectal carcinomas express HLA class II but not B7-1 and B7-2 costimulatory molecules of the T-cell activation.
    Chaux P; Moutet M; Faivre J; Martin F; Martin M
    Lab Invest; 1996 May; 74(5):975-83. PubMed ID: 8642792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HER-2/neu-derived peptide 884-899 is expressed by human breast, colorectal and pancreatic adenocarcinomas and is recognized by in-vitro-induced specific CD4(+) T cell clones.
    Perez SA; Sotiropoulou PA; Sotiriadou NN; Mamalaki A; Gritzapis AD; Echner H; Voelter W; Pawelec G; Papamichail M; Baxevanis CN
    Cancer Immunol Immunother; 2002 Jan; 50(11):615-24. PubMed ID: 11807625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antigen presentation to naive CD4 T cells in the lymph node.
    Itano AA; Jenkins MK
    Nat Immunol; 2003 Aug; 4(8):733-9. PubMed ID: 12888794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.